D. M. Gershenson

1.5k total citations
62 papers, 1.1k citations indexed

About

D. M. Gershenson is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, D. M. Gershenson has authored 62 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Reproductive Medicine, 19 papers in Obstetrics and Gynecology and 18 papers in Surgery. Recurrent topics in D. M. Gershenson's work include Ovarian cancer diagnosis and treatment (34 papers), Endometrial and Cervical Cancer Treatments (14 papers) and Endometriosis Research and Treatment (9 papers). D. M. Gershenson is often cited by papers focused on Ovarian cancer diagnosis and treatment (34 papers), Endometrial and Cervical Cancer Treatments (14 papers) and Endometriosis Research and Treatment (9 papers). D. M. Gershenson collaborates with scholars based in United States, Thailand and Spain. D. M. Gershenson's co-authors include Michael B. Morris, Thomas W. Burke, L. Copeland, J. Taylor Wharton, C. Allen Stringer, Felix N. Rutledge, Larry J. Copeland, Creighton L. Edwards, Kevin R. Brader and Ralph S. Freedman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

D. M. Gershenson

58 papers receiving 1.1k citations

Peers

Countries citing papers authored by D. M. Gershenson

Since Specialization

Citations

This map shows the geographic impact of D. M. Gershenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. M. Gershenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. M. Gershenson more than expected).

Fields of papers citing papers by D. M. Gershenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. M. Gershenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. M. Gershenson. The network helps show where D. M. Gershenson may publish in the future.

Co-authorship network of co-authors of D. M. Gershenson

This figure shows the co-authorship network connecting the top 25 collaborators of D. M. Gershenson. A scholar is included among the top collaborators of D. M. Gershenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. M. Gershenson. D. M. Gershenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance 2019 ·Gynecologic Oncology ·Lauren Cobb, (unknown), Revathy B. Iyer, Alpa M. Nick, Nicole D. Fleming, Anil K. Sood, Kwok‐Kin Wong, (unknown), D. M. Gershenson	1
2	Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. 2011 ·Journal of Clinical Oncology ·Erin R. King, Yvonne T.M. Tsang, Z. Zu, D. M. Gershenson, Samuel C. Mok, (unknown)	0
3	A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC) 2008 ·Journal of Clinical Oncology ·Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Melissa Munsell, Lois M. Ramondetta, (unknown), Robert L. Coleman, Clare Walker, D. M. Gershenson, Thomas W. Burke, (unknown)	33
4	Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction 2008 ·International Journal of Gynecological Cancer ·(unknown), Yan Li, (unknown), Hong Zheng, D. M. Gershenson, (unknown)	1
5	Systemic anticancer therapy in gynecological cancer patients with renal dysfunction 2007 ·International Journal of Gynecological Cancer ·(unknown), (unknown), Wei Hu, James H. Liu, Kevin W. Finkel, D. M. Gershenson, J. J. Kavanagh	2
6	Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction 2007 ·International Journal of Gynecological Cancer ·(unknown), Yisheng Li, (unknown), Hong Zheng, D. M. Gershenson, J. J. Kavanagh	5
7	Overexpression of the centrosomal protein aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients 2005 ·Journal of Clinical Oncology ·Charles N. Landen, Anand Immaneni, Michael T. Deavers, Alison J. Thornton, Joseph Celestino, (unknown), Liying Han, Diane C. Bodurka, D. M. Gershenson, William R. Brinkley, Anil K. Sood	2
8	Paget's Disease of the Vulva: Pathology, Pattern of Involvement, and Prognosis 2001 ·Journal of Lower Genital Tract Disease ·(unknown), (unknown), Diane C. Bodurka, Michael T. Deavers, (unknown), Jane Shen-Gunther, D. M. Gershenson	11
9	Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. 1998 ·Journal of Clinical Oncology ·Michael B. Morris, Kevin R. Brader, Charles Levenback, Thomas W. Burke, E. Neely Atkinson, (unknown), D. M. Gershenson	59
10	Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. 1998 ·Journal of Clinical Oncology ·Kevin R. Brader, Michael J. Morris, C. Levenback, Lawrence B. Levy, (unknown), D. M. Gershenson	58
11	Salvage surgery for chemorefractory gestational trophoblastic disease. 1994 ·Journal of Clinical Oncology ·Erik Lehman, D. M. Gershenson, Thomas W. Burke, Charles Levenback, (unknown), Michael B. Morris	46
12	Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence 1992 ·International Journal of Gynecology & Obstetrics ·(unknown), (unknown), (unknown), Michael B. Morris, D. M. Gershenson, J. Taylor Wharton	44
13	Endometrioid carcinoma of the ovary: Retrospective review of 145 cases 1991 ·International Journal of Gynecology & Obstetrics ·Richard Kline, J.Taylor Wharton, E. Neely Atkinson, Thomas W. Burke, D. M. Gershenson, Cynthia Edwards	8
14	Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide 1990 ·Gynecologic Oncology ·Thomas W. Burke, C. Allen Stringer, Michael B. Morris, Ralph S. Freedman, D. M. Gershenson, J. J. Kavanagh, Creighton L. Edwards	53
15	Treatment of metastatic stromal tumors of the ovary with cis‐platin, doxorubicin, and cyclophosphamide 1988 ·International Journal of Gynecology & Obstetrics ·D. M. Gershenson, L. Copeland, (unknown)	29
16	Stage IB cervical carcinoma treated with radical hysterectomy and pelvic lymphadenectomy: role of adjuvant radiotherapy. 1987 ·PubMed ·(unknown), (unknown), L. Copeland, D. M. Gershenson, (unknown), Rutledge Fn	51
17	Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. 1986 ·PubMed ·Ralph S. Freedman, Patton B. Saul, (unknown), (unknown), D. M. Gershenson, Lynne A. Jones, E. Neely Atkinson, (unknown)	19
18	Definitive radiotherapy in the treatment of carcinoma of the cervix with bladder invabion 1986 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), D. M. Gershenson, Marsha D. McNeese	3
19	Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trial. 1985 ·PubMed ·J. J. Kavanagh, Patton B. Saul, D. M. Gershenson, Larry J. Copeland, J.Taylor Wharton	2
20	Microscopic disease at second-look laparotomy in advanced ovarian cancer 1983 ·Gynecologic Oncology ·(unknown), D. M. Gershenson, J.Taylor Wharton, Cynthia Edwards, Felix N. Rutledge	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact